Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients

Adolfo Aleman¹, Oliver Van Oekelen¹, Bhaskar Upadhyaya², Katherine Beach³, Ariel Kogan Zajdman², Hala Alshammary³, Kseniya Serebryakova², Sarita Agte², Katerina Kappes², Charles R Gleason⁴, Komal Srivastava³; PVI/MM/Seronet Study Group; Steve Almo⁵, Carlos Cordon-Cardo⁶, Florian Krammer³, Miriam Merad⁷, Sundar Jagannath², Ania Wajnberg⁸, Viviana Simon⁹, Samir Parekh¹⁰

Collaborators, Affiliations

Collaborators

PVI/MM/Seronet Study Group:
D Andre, A Azad, R Banu, M C Bermúdez-González, G Cai, A Chari, H Cho, C Cognigni, K David, D Floda, A Firpo, G Kleiner, N Lyttle, W Mendez, L C F Mulder, R Mendu, A Oostenink, A Rooker, S Richard, J Richter, C Rodriguez, A Rossi, K Russo, L Sanchez, A Salimbangon, M Saksena, A Shin, L Sominsky, D Verina

Affiliations

¹ Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Department of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁴ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁵ Department of Biochemistry, Albert Einstein College of Medicine, New York, NY, USA.
⁶ Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁷ Department of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁸ Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, NY, USA.
⁹ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Division of Infectious Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: viviana.simon@mssm.edu.
¹⁰ Department of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: samir.parekh@mssm.edu.

PMID: 35390296
PMCID: PMC8983835
DOI: 10.1016/j.ccell.2022.03.013

Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients

Adolfo Aleman et al. Cancer Cell. 2022.

. 2022 May 9;40(5):441-443.

doi: 10.1016/j.ccell.2022.03.013. Epub 2022 Apr 6.

Authors

Collaborators

PVI/MM/Seronet Study Group:
D Andre, A Azad, R Banu, M C Bermúdez-González, G Cai, A Chari, H Cho, C Cognigni, K David, D Floda, A Firpo, G Kleiner, N Lyttle, W Mendez, L C F Mulder, R Mendu, A Oostenink, A Rooker, S Richard, J Richter, C Rodriguez, A Rossi, K Russo, L Sanchez, A Salimbangon, M Saksena, A Shin, L Sominsky, D Verina

Affiliations

¹ Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Department of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁴ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁵ Department of Biochemistry, Albert Einstein College of Medicine, New York, NY, USA.
⁶ Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁷ Department of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Human Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁸ Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, NY, USA.
⁹ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Division of Infectious Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogen Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: viviana.simon@mssm.edu.
¹⁰ Department of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: samir.parekh@mssm.edu.

PMID: 35390296
PMCID: PMC8983835
DOI: 10.1016/j.ccell.2022.03.013

No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Viviana Simon and Carlos Cardon-Cordo are listed on the serological assay patent application as co-inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Ajai Chari reports grants and personal fees from Janssen, Bristol Myers Squibb (Celgene), Amgen, Seattle Genetics, and Millennium Pharmaceuticals/Takeda and personal fees from Karyopharm, Sanofi, Oncopeptides, Antengene, Glaxo Smith Kline, Secura Bio, Shattuck Labs, Genentech, and Abbvie. Florian Krammer reports grants and personal fees from Pfizer and personal fees from Seqirus and Avimex. The Krammer laboratory is collaborating with Pfizer on animal models of SARS-CoV-2. Sundar Jagannath reports consulting fees for Bristol Myers Squibb (Celgene), Janssen, Karyopharm Therapeutics, Merck, Sanofi, and Takeda Pharmaceuticals. Samir Parekh reports consulting fees from Foundation Medicine and research funding from Bristol Myers Squibb (Celgene), Karyopharm, and Amgen. The other authors reported no relevant conflicts of interest.

References

1. Addeo A., Shah P.K., Bordry N., Hudson R.D., Albracht B., Di Marco M., Kaklamani V., Dietrich P.-Y., Taylor B.S., Simand P.-F., et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021;39:1091–1098.e2. - PMC - PubMed
1. Aleman A., Upadhyaya B., Tuballes K., Kappes K., Gleason C.R., Beach K., Agte S., Srivastava K., Van Oekelen O., Barcessat V., et al. PVI/Seronet Study Group Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. Cancer Cell. 2021;39:1442–1444. - PMC - PubMed
1. Bar-On Y.M., Goldberg Y., Mandel M., Bodenheimer O., Freedman L., Kalkstein N., Mizrahi B., Alroy-Preis S., Ash N., Milo R., Huppert A. Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N. Engl. J. Med. 2021;385:1393–1400. - PMC - PubMed
1. Barda N., Dagan N., Cohen C., Hernán M.A., Lipsitch M., Kohane I.S., Reis B.Y., Balicer R.D. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021;398:2093–2100. - PMC - PubMed
1. McCallum M., Czudnochowski N., Rosen L.E., Zepeda S.K., Bowen J.E., Walls A.C., Hauser K., Joshi A., Stewart C., Dillen J.R., et al. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. Science. 2022;375:864–868. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients

Collaborators

Affiliations

Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients

Authors

Collaborators

Affiliations

Conflict of interest statement

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources